Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.
A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.
Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...
The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...
He's lost his father, a brother, aunts, uncles and extended family members to cancer — many of them in their 30s and 40s.
On February 2, 2026, U.S. District Judge Joshua D. Wolson made several key summary judgment rulings in advance of trial in ...
MarketBeat on MSN
MarketBeat Week in Review – 01/19 - 01/23
After moving sharply lower on tariff fears to start the week, stocks rallied as most economic indicators point to an economy that’s growing strongly. An in-line reading on the November PCE inflation ...
Some periods of history are so bizarre that even if you’ve lived through them, looking back on them feels surreal, as though ...
According to Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology, preclinical studies using <ALPHA>DAT-EVs loaded with curcumin have demonstrated promising therapeutic effects in both ...
A world-first trial in Australia will treat children with advanced brain cancer using technology from the COVID-19 jab.
A growing body of research continues to reveal information about the Covid virus and its ability to cause harm long after ...
Australia has launched the world’s first clinical trial testing personalized mRNA cancer vaccines in children suffering from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results